20.71
0.60 (3.01%)
| Previous Close | 20.10 |
| Open | 20.21 |
| Volume | 929,588 |
| Avg. Volume (3M) | 8,446,373 |
| Market Cap | 14,400,153,600 |
| Price / Sales | 714.40 |
| Price / Book | 3.32 |
| 52 Weeks Range | |
| Earnings Date | 9 Feb 2026 |
| Operating Margin (TTM) | -4,823.84% |
| Diluted EPS (TTM) | -0.750 |
| Quarterly Revenue Growth (YOY) | -16.10% |
| Quarterly Earnings Growth (YOY) | -96.70% |
| Total Debt/Equity (MRQ) | 1.93% |
| Current Ratio (MRQ) | 33.47 |
| Operating Cash Flow (TTM) | -839.45 M |
| Levered Free Cash Flow (TTM) | -375.20 M |
| Return on Assets (TTM) | -10.73% |
| Return on Equity (TTM) | -12.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Roivant Sciences Ltd. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | -0.25 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 30.31% |
| % Held by Institutions | 83.49% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 26.00 (Citigroup, 25.57%) | Buy |
| Median | 20.50 (-0.99%) | |
| Low | 16.50 (B of A Securities, -20.31%) | Hold |
| Average | 21.19 (2.34%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 15.82 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 11 Nov 2025 | 26.00 (25.57%) | Buy | 20.90 |
| 29 Oct 2025 | 25.00 (20.74%) | Buy | 18.76 | |
| B of A Securities | 18 Sep 2025 | 16.50 (-20.31%) | Hold | 15.09 |
| Goldman Sachs | 18 Sep 2025 | 24.00 (15.91%) | Buy | 15.09 |
| Guggenheim | 18 Sep 2025 | 21.00 (1.42%) | Buy | 15.09 |
| HC Wainwright & Co. | 18 Sep 2025 | 20.00 (-3.40%) | Buy | 15.09 |
| JP Morgan | 18 Sep 2025 | 20.00 (-3.40%) | Buy | 15.09 |
| Jefferies | 18 Sep 2025 | 20.00 (-3.40%) | Buy | 15.09 |
| Leerink Partners | 18 Sep 2025 | 22.00 (6.25%) | Buy | 15.09 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |